comparemela.com
Home
Live Updates
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting : comparemela.com
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters
Related Keywords
Australia ,
Germany ,
Shanghai ,
China ,
United States ,
Boston ,
Massachusetts ,
Beijing ,
Heidelberg ,
Baden Wüberg ,
Chicago ,
Illinois ,
America ,
Haimen Jiangsu ,
Prnewswire Eucure Biopharma ,
Biocytogen Eucure Biopharma ,
Kostenloser Wertpapierhandel ,
Eucure Biopharma ,
Zimeng Zhang ,
Vinod Ganju ,
Biocytogen Pharmaceuticals Beijing Co Ltd ,
Biocytogen Pharmaceuticals ,
Project Integrum ,
Eucure Biopharma Contacts ,
Biocytogen ,
Bucure ,
Iopharma ,
Present ,
Linical ,
Data ,
Rom ,
H003 ,
Anti ,
Cd40 ,
H001 ,
Tla ,
Trials ,
022 ,
American ,
Society ,
Ncology ,
Disco ,
Nnual ,
Meeting ,
comparemela.com © 2020. All Rights Reserved.